ALA

AROVELLA FPO [ALA]
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Healthcare · ASX Small Cap
$0.0600 +0.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-03-02
Get alerts when ALA triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track ALA — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Strong cash runway (8 quarters)
  • Strong revenue growth (+34746%)
  • Near 52-week low (4% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (12%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +34746% — the top line is moving in the right direction
  • Altman Z-Score distress zone (1.77 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-198%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 35% over the past year

Expected next for ALA

1 Nov 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 23 Oct to 10 Nov
The last 4 moved ALA -2.6% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

LOW Notification of 2026 AGM Date
LOW Appendix 4E and Annual Report
NONE Clinical manufacturing batch released, first site activated
NONE Corporate Governance Statement
NONE Appendix 4G

Recent ASX Announcements

2026-09-08 Notification of 2026 AGM Date
2026-09-06 Clinical manufacturing batch released, first site activated PRICE SENSITIVE
2026-08-20 Corporate Governance Statement
2026-08-20 Appendix 4G
2026-08-20 Appendix 4E and Annual Report PRICE SENSITIVE

Key Metrics

$73.7M
Market Cap
548K
Avg Volume
0.7x
Vol Ratio
$0.06 — $0.12
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-40.4%
ROE
-197.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 79%
LLeader vs LaggardlaggardRS: -10
IInstitutional SponsorshippassInst: 12%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:ALA vs NUZALA vs IPDALA vs HIQ
Share this analysis

Track ALA and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required